[ad_1]
Several potential vaccines are currently undergoing “accelerated testing” and Brussels stands by its prediction that one of them could be approved and available “early next year,” the source said.
Previously, pharmaceutical giants Pfizer and BioNTech reported that 90% of their vaccines developed jointly. effectively protects against COVID-19 coronavirus infection, giving hope that the pandemic will be overcome soon.
Accelerated procedure
The European Medicines Agency has launched an accelerated screening procedure for potential vaccines and no reports have yet been received ruling out their safety and efficacy.
However, a spokeswoman for the Amsterdam-based EMA said no clinical trial results had been received so far.
“In an expedited inspection, the EMA may exceptionally evaluate the (research) data, when available, before formally applying for a product marketing authorization,” he said.
“We evaluated the first batch of vaccine data from laboratory (non-clinical) studies,” he said.
“The Agency is currently evaluating a second batch of data related to the quality of the vaccine, including data on its ingredients and its method of manufacture,” said an EMA spokeswoman.
“All new data related to this vaccine will be evaluated in the same way. So far, we have not received or evaluated the clinical (test) data received and therefore we cannot comment further,” he said.
In Brussels at the time, another source confirmed this information, but added that “it is risky to publish predictions”, although there are indications that the vaccine “may be available early next year.”
European officials, including the head of the European Commission, Ursula von der Leyen, have previously indicated this deadline for the vaccine to appear.
Brussels has planned to fund tens of millions of doses of vaccines from various companies, including the American pharmaceutical giant Pfizer and its German partner BioNTech.
[ad_2]
